A 52-year-old postmenopausal woman from Mumbai presents with a 3-month history of a painless, hard lump in the upper outer quadrant of the left breast. On examination, the mass is 2 cm, fixed to the chest wall, with skin dimpling and retraction of the nipple. Axillary lymph nodes are palpable and firm. Mammography shows a spiculated lesion with microcalcifications. Core needle biopsy reveals infiltrating ductal carcinoma with moderate nuclear pleomorphism and 12 mitoses per 10 high-power fields. Immunohistochemistry shows ER+, PR+, HER2 negative. Which of the following is the most appropriate next step in management?

Explanation

## Clinical Assessment This patient presents with **locally advanced breast cancer** with the following features: - 2 cm mass fixed to the chest wall (T4b — chest wall involvement) - Skin dimpling and nipple retraction (skin involvement) - Palpable, firm axillary lymph nodes (N1) - Moderate-grade histology (12 mitoses/10 HPF, Grade 2–3) - ER+, PR+, HER2 negative ## Staging **Key Point:** Fixation to the chest wall classifies this tumor as **T4a** (involvement of chest wall), and with palpable axillary nodes (N1), this is at minimum **Stage IIIA–IIIB disease**. Skin dimpling and nipple retraction further support locally advanced disease. ## Why Neoadjuvant Chemotherapy First? Per current NCCN, ESMO, and standard Indian oncology guidelines (as reflected in Robbins & Cotran and DeVita's Cancer Principles): 1. **Chest wall fixation (T4)** — This is a hallmark of locally advanced breast cancer (LABC). Direct surgery without downstaging carries high risk of incomplete resection (positive margins). 2. **Neoadjuvant chemotherapy (NACT)** — Recommended for T4 disease to downstage the tumor, improve resectability, assess in-vivo chemosensitivity, and potentially allow breast conservation in select cases. 3. **Axillary nodal disease (N1)** — NACT can convert node-positive to node-negative disease, improving surgical outcomes. 4. **ER+/PR+ status** — Does not preclude chemotherapy; hormonal therapy is given adjuvantly after surgery, not as primary treatment for operable/locally advanced disease. **High-Yield:** T4 disease (chest wall or skin involvement) is the standard indication for **neoadjuvant chemotherapy** followed by surgery (mastectomy), not upfront mastectomy. This is the current standard of care per NCCN guidelines and is well-established in Harrison's Principles of Internal Medicine and DeVita's Oncology. ## Management Algorithm | Feature | Implication | |---------|-------------| | T4 (chest wall fixation) | Neoadjuvant chemotherapy → reassess → surgery | | N1 (palpable axillary nodes) | ALND at time of definitive surgery | | ER+, PR+ | Adjuvant endocrine therapy (aromatase inhibitor preferred in postmenopausal) | | HER2 negative | No trastuzumab | | Postmenopausal | Aromatase inhibitor (letrozole/anastrozole) over tamoxifen | ## Why Other Options Are Incorrect? - **B) Hormone therapy alone** — Never appropriate as sole treatment for operable/locally advanced breast cancer; hormonal therapy is adjuvant. - **C) Wide local excision + SLNB** — Contraindicated: chest wall fixation and skin involvement are absolute contraindications to breast conservation; SLNB is inappropriate with clinically positive nodes. - **D) Modified radical mastectomy upfront** — Upfront surgery without NACT is inappropriate for T4 disease; NACT is required first to downstage and optimize resection margins. **Clinical Pearl:** Per Harrison's and NCCN guidelines, **T4 breast cancer** (chest wall or skin involvement) mandates neoadjuvant chemotherapy before definitive surgery. Modified radical mastectomy follows NACT once the tumor is downstaged and deemed resectable.